Allion Healthcare Inc. (ALLI) is a national provider of specialty pharmacy and disease management services focused on HIV/AIDS patients. The company recently reported better-than-expected 1Q09 net income of $3.5M, or EPS of $0.13, compared with net income of $1.1M and EPS of $0.06 in 1Q08.
Organic growth in 1Q09 of the company’s core Specialty HIV was 9% y/y, with the aggregate number of Specialty HIV prescriptions
filled in 4Q08 tallying 265,455, an increase of 3.7% y/y.
We believe current initiatives, such as the partnering with large AIDS service organizations in Seattle, for example, bodes well for increased volume growth over the short term. We maintain our BUY rating at current levels.Zacks Investment Research
